novartis_rm_logo_pos_rgb.png

Post-ESMO update & “What now for CDK4/6 inhibitors?” 
8th November 2022 | 18:30 – 20:00 GMT

This promotional meeting is organised and funded by Novartis Pharmaceuticals UK Ltd.

UK | November 2022 | 248254

Your attendance at the event is governed by our Healthcare Professional Event Attendance Terms. By attending the event, you are agreeing to be bound by such terms.

Adverse events should be reported. Reporting forms and information can be found at  www.mhra.gov.uk/yellowcard (UK).

Adverse events should also be reported to Novartis via  uk.patientsafety@novartis.com or online through the pharmacovigilance intake (PVI) tool at  www.report.novartis.com

If you have a question about a product, please contact Medical Information on 01276 698370 or by email at  medinfo.uk@novartis.com